PatientPoint names CEO
ORLANDO, Fla. PatientPoint, whose core offering is a self-service kiosk that automates check-in and check-out processes in retail clinic environments and physician offices, has named Raj Toleti CEO.
Previously, Toleti founded Galvanon, a technology company focused on improving the patient experience, which was acquired by NCR in 2005. While at Galvanon, he oversaw the introduction of the first commercially available patient self-service kiosk and software platform to automate patient check-in and intake processes at hospitals and physician offices.
In other company news, PatientPoint has inked new contracts with five organizations: Florida Cardiology, Southlake Orthopaedics, University Internal Medicine and Diabetes Associates, Clara Roman, M.D., and BillingNetwork.
Merck gets nod from FDA for Dulera
WHITEHOUSE STATION, N.J. The Food and Drug Administration has approved a new drug by Merck for treating asthma in patients ages 12 years and older, Merck said Thursday.
The FDA approved Dulera (mometasone furoate and formoterol fumarate dihydrate), an inhaled, fixed-dose combination asthma treatment.
“Despite the advances made in the treatment of asthma in recent years, many patients may still not be well-controlled on their current therapies,” University of Tennessee Health Science Center medical professor Michael Blaiss said in a statement on behalf of Merck. “Asthma control is an important treatment goal, and Dulera provides a new option for physicians to help manage this chronic condition in appropriate patients.”
FDA approves Mylan’s version of Procardia XL
PITTSBURGH The Food and Drug Administration has approved a generic drug made by Mylan for heart disease, Mylan said Thursday.
Mylan announced the approval of nifedipine extended-release tablets in the 30, 60 and 90 mg strengths. The drug is used to treat hypertension and angina.
The drug is a generic version of Pfizer’s Procardia XL. Branded and generic versions of the drug had sales of around $234 million during the 12-month period ended in March, according to IMS Health.